Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
Goldman Sachs downgraded Regenxbio Inc (NASDAQ:RGNX), citing gene therapy’s appeal for wet AMD and diabetic retinopathy is ...
devdiscourse6d
AI steps up in the battle against diabetes complications
AI has demonstrated considerable potential in diabetic foot (DF) management. AI-powered thermal imaging and predictive ...
Too Old to Operate15d
Q&A: Our Role in Reducing Diabetic Retinopathy Mortality
Three experts discuss the increased mortality risk for patients with diabetic retinopathy, available screening tools, and ...
Medical News Today14d
What do fundus photos show in diabetic retinopathy?
Diabetic retinopathy is an eye disease that can develop in people with diabetes. Without treatment, it can lead to vision loss and blindness. Fundus photography forms part of fundoscopy ...
Mint26d
Will my insurance cover daycare treatment of retinopathy?
Insurance coverage for intravitreal injections, an essential treatment for diabetic retinopathy, depends on the specific terms and conditions of an individual’s health insurance policy.
Pharm Exec7d
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...
Pharmabiz20h
Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema
Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...
Endocrinology Advisor5d
Susvimo Approval Expanded to Include Diabetic Macular Edema
The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.
Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to ...
Business Wire7d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
USA News Group: FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape
USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Feb. 11, 2025 /PRNewswire/ -- USA News Group News Commentary - Weeks after the monumental ...